Thermo Fisher Scientific Cash Flow Statement
TMO / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Thermo Fisher Scientific generated $7.8B in operating cash flow and $6.3B in free cash flow in FY2025. Free cash flow margin was 14.1% of revenue.
Based on SEC 10-K filings.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $6.7B | $6.3B | $7.7B | $6.4B | $3.7B | $6.4B | $3.7B | - | - | - | - | - | $336.2M | $277.3M | $1.3B |
| Depreciation & Amortization | - | - | $831.0M | $658.0M | $564.0M | - | - | $2.3B | $2.0B | $1.8B | $1.7B | $1.7B | $999.9M | $983.7M | $859.6M |
| Operating Cash Flow | $7.8B | $8.7B | $9.3B | $8.3B | $5.0B | $8.3B | $5.0B | $4.5B | $4.0B | $3.3B | $2.9B | $2.6B | $2.0B | $2.0B | $1.7B |
| Capital Expenditures | $1.5B | $1.4B | $2.5B | $1.5B | $926.0M | $1.5B | $926.0M | $758.0M | $508.0M | $444.0M | $423.0M | $427.6M | $282.4M | $315.1M | $260.9M |
| Free Cash Flow | $6.3B | $7.3B | $6.8B | $6.8B | $4.0B | $6.8B | $4.0B | $3.8B | $3.5B | $2.8B | $2.5B | $2.2B | $1.7B | $1.7B | $1.4B |
| Share Buybacks | $3.0B | $4.0B | $2.0B | $1.5B | $1.5B | $1.5B | $1.5B | $500.0M | $750.0M | $1.3B | $500.0M | $0 | $89.8M | $1.1B | $1.3B |
| Dividends Paid | $636.0M | $583.0M | $395.0M | $337.0M | $297.0M | $337.0M | $297.0M | $266.0M | $237.0M | $238.0M | $241.0M | $234.8M | $216.2M | $142.2M | $0 |
| FCF Margin | 14.1% | 17.0% | 17.3% | 21.1% | 15.8% | 21.1% | 15.8% | 15.5% | 73.4% | 15.4% | 14.8% | 13.0% | 13.2% | 13.8% | 12.4% |